Pay in 4 interest-free payments of $5.39 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Clinical trials used doses as high as 1 mg per day without safety concerns, but 300 mcg is the most commonly referenced dose in peptide medicine literature and in the investigational protocols that have been published since the formal trials concluded
Neither route is proven better in people
not primarily appetite-driven (OUP Academic) Expected weight loss (this is where many people get misled) In major obesity trials: Semaglutide 2.4 mg weekly: ~14.9% mean weight loss at 68 weeks (STEP-1) (PubMed) Tirzepatide: ~15.0% to ~20.9% mean weight loss at 72 weeks , dose-dependent (SURMOUNT-1) (PubMed) AOD-9604s best-known human signal is kilograms, not double-digit percentages , and later studies did not sustain a strong obesity-drug profile
Once reconstituted, solutions require immediate refrigeration between 2C to 8C to maintain molecular integrity over subsequent experimental phases
/assets/images/provider/photos/2702244.jpeg)
It is not a drug, food, or cosmetic, and must not be misrepresented, misused, or mislabeled as such.
Early research is mostly preclinical, so it should not be treated as a proven anti-aging or fat-loss treatment
